New Stocks News | Medical solutions provider Makeyden submits application to Hong Kong Stock Exchange, with net profit for the first half of the year approximately 40.968 million yuan.

According to the disclosure on September 11 by the Hong Kong Stock Exchange, Shenzhen MicroPort Biomedical Technology Co., Ltd. ("MicroPort") has submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with Morgan Stanley and Huatai International acting as joint sponsors. According to the prospectus, MicroPort is a global provider of medical solutions, with profits of approximately 40.968 million RMB in the first half of this year. The prospectus shows that MicroPort offers an innovative and comprehensive product portfolio to meet the clinical needs of a wide range of clinical departments, wards, clinics, community health centers, laboratories, and home care settings within medical institutions. As of June 30, 2025, MicroPort has commercialized over (i) 50 life support products, (ii) 80 minimally invasive intervention products, and (iii) 210 in vitro diagnostic products, with various models to meet different application needs. By the last practicable date, MicroPort's products have reached over 140 countries and regions worldwide. In China, MicroPort's products have covered over 6,000 hospitals, including approximately 90% of tertiary grade A hospitals, spanning 31 provinces, municipalities, and autonomous regions. In terms of life support, MicroPort has developed a range of innovative life support products, including the world's first remote infusion control system, China's first domestically developed multi-channel infusion workstation, infusion workstations compatible with MRI environments, touchscreen infusion pumps, touchscreen syringe pumps, and touchscreen enteral feeding pumps. By sales revenue, MicroPort ranked first in the infusion workstation market in China from 2018 to 2024, and by sales revenue, MicroPort ranked first in the enteral feeding pump market from 2021 to 2024. Regarding minimally invasive interventions, MicroPort is one of the few domestic brands in China with a full range of proprietary endoscopic products, including reusable and disposable endoscopic systems and related consumables. By sales revenue, MicroPort ranked second in the Chinese digestive system minimally invasive intervention consumables market from 2022 to 2024; by sales revenue, MicroPort ranked among the top five in the Chinese disposable choledochoscope market from 2023 to 2024. In terms of in vitro diagnostics, MicroPort launched the world's first fully automatic thromboelastogram analyzer in 2021, ranking first in the Chinese market by sales revenue from 2021 to 2024. Additionally, by sales revenue, the company ranked among the top five in the Chinese blood typing equipment market in 2024. MicroPort has established a wide business presence globally, offering medical products across various regions such as the Asia Pacific, Europe, the Middle East and Africa, and the Americas. The company strategically set up five research and development centers and six production centers in China and the UK. To enhance international service capabilities, MicroPort has local representatives in strategic markets such as the UK, Netherlands, Belgium, Turkey, India, Thailand, Indonesia, Mexico, Brazil, and Colombia, ensuring timely and localized support to global customers. Financially, the company's revenue for the years 2022, 2023, 2024, and the six months ending June 30, 2025 was approximately 917 million RMB, 1.313 billion RMB, 1.399 billion RMB, and 787 million RMB respectively. During the same period, the company reported losses of approximately 226.161 million RMB, 645.08 million RMB, 966.17 million RMB in 2022, 2023, and 2024, respectively, before turning a profit of 40.968 million RMB in the six months ending June 30, 2025. According to the risk factors mentioned by MicroPort in the prospectus, the market size, average selling price, and sales volume of the company's products, as well as its market share in competitive markets, may decline, which could have a significant adverse impact on the company's business performance and financial condition.